Edwards Lifesciences Co. (NYSE:EW) Shares Purchased by Manitou Investment Management Ltd.

Manitou Investment Management Ltd. raised its position in Edwards Lifesciences Co. (NYSE:EW) by 22.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 179,451 shares of the medical research company’s stock after purchasing an additional 32,781 shares during the quarter. Edwards Lifesciences comprises approximately 2.6% of Manitou Investment Management Ltd.’s investment portfolio, making the stock its 15th biggest holding. Manitou Investment Management Ltd.’s holdings in Edwards Lifesciences were worth $13,285,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in EW. Bowman & Co S.C. raised its position in shares of Edwards Lifesciences by 1.2% during the 4th quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock worth $924,000 after buying an additional 148 shares in the last quarter. JFS Wealth Advisors LLC increased its stake in shares of Edwards Lifesciences by 31.1% during the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 166 shares during the period. Seascape Capital Management raised its holdings in Edwards Lifesciences by 0.5% during the third quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock worth $2,177,000 after purchasing an additional 174 shares in the last quarter. Cooper Financial Group lifted its position in Edwards Lifesciences by 2.8% in the fourth quarter. Cooper Financial Group now owns 6,466 shares of the medical research company’s stock worth $479,000 after purchasing an additional 175 shares during the period. Finally, Martin Capital Advisors LLP boosted its stake in Edwards Lifesciences by 0.7% during the 3rd quarter. Martin Capital Advisors LLP now owns 25,546 shares of the medical research company’s stock valued at $1,686,000 after purchasing an additional 186 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

EW has been the topic of a number of research reports. Daiwa America downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Citigroup boosted their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. JPMorgan Chase & Co. raised their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Evercore ISI dropped their target price on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. Finally, Canaccord Genuity Group increased their target price on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the company a “hold” rating in a research note on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $78.48.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at $3,077,593.52. This represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 33,000 shares of company stock worth $2,195,180. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

EW stock opened at $68.95 on Friday. The firm has a 50 day simple moving average of $72.25 and a 200 day simple moving average of $70.86. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The stock has a market cap of $40.66 billion, a P/E ratio of 9.95, a P/E/G ratio of 3.54 and a beta of 1.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same quarter last year, the business posted $0.59 EPS. The company’s revenue for the quarter was up 8.9% on a year-over-year basis. Research analysts anticipate that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.